YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFRL858R, T790M-mutant resistance in vitro and in vivo
Abstract
YL143 was identified as a novel wild-type sparing EGFRT790M inhibitor with good pharmacokinetic properties. It potently suppresses EGFRL858R/T790M with an 50% inhibitory concentration (IC50) value of 2.0 ± 0.3 nmol/L, but is approximately 92-folds less potent against EGFRWT kinase. YL143 suppresses cellular proliferation and induces G0/G1 phase arrest and apoptosis in H1975 cells with EGFRL858R/T790M mutation at 30 nmol/L. It also exhibits acceptable pharmacokinetics (PK) parameters with an oral bioavailability value of 25.0% after oral administration in rats and exhibits promising antitumor efficacy in a gefitinib-resistant human H1975 xenografted model after oral administration of 30 mg/kg/day. These data supported that YL143 could be a promising lead compound for overcoming clinical EGFRT790M resistance of patients with non-small-cell lung cancer (NSCLC).
Introduction
Lung cancer is a leading cause of cancer-related death worldwide 1, 2. Non-small-cell lung cancers (NSCLC) that comprise almost 85% of all human lung tumors include squamous cell carcinoma, adenocarcinoma, and large-cell lung cancer 3, 4. Genetic aberrations within the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) such as L858R mutation and E746-A750 deletion have been observed in approximately 30% patients with NSCLC and have been identified as key drivers of NSCLC progression 5, 6. Abnormal activation of EGFR leads to overactivation of downstream Ras-Raf-MAPK and PI3K-AKT pathways associated with tumor growth and poor outcome 4, 7.
The first-generation EGFR kinase inhibitors, for example, gefitinib and erlotinib, produce reliable responses and survival benefits in patients with NSCLC with EGFR activating mutation. However, the rapid emergence of acquired resistance limits their clinical efficacy 8. Approximately 50% of resistant patients harbor a secondary threonine790 to methionine790 mutation in EGFR kinase domain 9. The second-generation inhibitors such as afatinib were developed consequently with the aim to overcome the EGFRT790M mutation-mediated resistance 10. However, most of the second-generation inhibitors display relatively low therapeutic window in resistance patients because of their poor selectivity over wild-type (WT) EGFR and/or poor pharmacokinetics parameters. In order to solve the “on-target” toxicity, several third-generation EGFRT790M-mutant selective inhibitors, for example, WZ4002 11, CO1686 (Rociletinib) 12, AZD9291 (Osimertinib) 13, 14, and HM61713 (BI1482694, Olmutinib) 15, were developed. Significantly, osimertinib had been approved by the FDA to treat the patients who exhibit resistance to gefitinib and erlotinib therapy and harbor EGFRT790M mutation. The latest clinical data demonstrated that osimertinib improved PFS (progression-free survival) from 10.2 to 18.9 months 16. However, the clinical investigation of CO1686 was terminated because of the strong IGF1R inhibitory activities of its metabolites causing hyperglycemia in about 40% patients 17-19.
Considerable efforts have been devoted to the development of third-generation EGFR inhibitors, and several series of small molecules with distinct chemical scaffolds were designed and synthesized as novel wild-type sparing EGFR inhibitors from our group 20-23. We have reported XTF262 as a highly potent and specific EGFRT790M inhibitor with an 50% inhibitory concentration (IC50) value of 0.8 nmol/L against EGFRL858R/T790M 20. However, this compound possessed a poor oral bioavailability value below 10% and exhibited little antitumor efficacy in a H1975 xenograft mouse model. Further structure-guided optimization helped us to obtain a new promising derivative YL143 which not only displayed strong and specific inhibition against EGFRT790M but also exhibited obviously improved pharmacokinetics (PK) properties with a rat bioavailability of 25.0% and good antitumor activity in vivo xenograft model.
Materials and Methods
Reagents and antibodies
YL143, N-(3-(2-((2-Methoxy-4-(4-methylpiperazin-1-yl)phenyl)amino)-5-methyl-7-oxopyrido [2,3-d]pyrimidin-8(7H)-yl)-5-methylphenyl)acrylamide, was designed and synthesized in our laboratory. The compound was dissolved in Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) at a concentration of 10 mmol/L and stored at −20°C. Primary antibodies against EGFR (#4267), phosphor-EGFR (#2234), ERK1/2 (#4695), phosphor-ERK1/2 (#4370), CDK2 (#2546), CDK4 (#2906), cyclin D2 (#3741), cyclin E (#4129), caspase-3 (#9665), caspase-9 (#9502), Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (#2118), and horseradish peroxidase (HRP)-linked secondary antibodies against rabbit or mouse were purchased from Cell Signaling Technology (Boston, MA).
Cell culture
H1975, HCC827, A549, and A431 were purchased from American type culture collection (ATCC). All cell lines were grown in RPMI-1640 or DMEM supplemented with 10% FBS and 1x penicillin/streptomycin solution (Invitrogen) in a humidified CO2 incubator at 37°C. All cells were in the logarithmic growth phase at the initiation of experiments.
In vitro kinase activity assay
All EGFR (WT, L858R, L858R/T790M, etc.) recombinant human protein was purchased from Invitrogen. The kinase activity assay was performed and optimized according to the instructions of Z’-LYTE™ kinase assay kits from the manufacturer (PV4879, Life, America). In our experiments, 10 concentration gradients from 0.01 nmol/L to 1.0 μmol/L were used for all the compounds.
Molecular docking studies
All the procedure was performed in Maestro 9.9 (Schrodinger LLC). The crystal structure of EGFR was taken from protein database bank (PDB ID 5GMP). The covalent bond between the inhibitor and the protein was deleted. Then, the protein was processed using the “Protein Preparation Wizard” workflow in Maestro 9.9 (Schrodinger LLC) to adding bond orders and hydrogens. All het atm residues and crystal water molecules beyond 5 Å from het group were removed. YL143 was built by in LigPrep module using OPLS-2005 force field. Glide module (covalent docking) was used as docking program. Michael addition was chosen as the reaction type. Cys797 was chosen as the reactive residue. The docking box was placed on the centroid of the binding ligand in the optimized crystal structure as described above. Covalent docking approach of Glide was adopted to dock YL143 to EGFR with the default parameters.
In vitro cell growth assay
Cells were seeded into 96-well plates at a density of 1500~3000/well in complete medium overnight. Then, cells were treated with various concentrations (0.01~1000 nmol/L) of YL143 for additional 3 days. Viable cell numbers were determined by Cell Counting Kit 8 (CCK8, CK04, Dojindo Laboratories, Japan). Each assay consisted of three replicate wells and repeated at least three times. IC50 values were calculated by inhibitor–response nonlinear regression curve fitting using GraphPad Prism 5.0 software (developed by Dr Harvey Motulsky, San Diego, CA 92037 USA). Each IC50 value was expressed as mean ± SD.
H1975 tumor xenograft
Male CB17-SCID mice were purchased from Vital River Laboratory Animal Technology Inc. (Beijing, China). H1975 cells (5 × 106/mouse) were injected subcutaneously in the right flanks of mice. When the mean tumor volume reached 100–200 mm3, tumor-bearing mice were randomized and treated with YL143 (30 mg/kg), CO1686 (30 mg/kg), and vehicle (10 mL/Kg) for the 18 consecutive days once daily by oral gavage, respectively. All the compounds were suspended in 0.5% CMC-Na aqueous solution. The tumor volume and body weight of animals were measured once every 2 days. Tumor volume was calculated as the L × W2/2 (L and W are the length and width of the tumor, respectively). All animal experiments were approved by the Institutional Animal Use and Care Committee of Guangzhou Institute of Biomedicine and Health, Chinese Academy of Science.
Western blot analysis
Cells were treated with various concentrations of compound for designed time. Then, cells were lysed using 1 × SDS sample lysis buffer (CST recommended) with protease and phosphatase inhibitors. Cell lysates were loaded and electrophoresed onto 8–12% SDS-PAGE gel, and then, separated proteins were transferred to a PVDF film. The film was blocked with 5% fat-free milk in TBS solution containing 0.5% Tween-20 for 4 h at room temperature and then incubated with corresponding primary antibody (1:1000–1:200) overnight at 4°C. After washing with TBST, HRP-conjugated secondary antibody was incubated for 2 h. And the protein signals were visualized by ECL Western Blotting Detection Kit (Thermo Scientific, Waltham, MA) and detected with Amersham Imager 600 system (GE, America).
Pharmacokinetic study
Sprague Dawley (SD) rats (180–220 g) were fasted overnight before drug administration. They could eat food and drink water freely during the study. Rats were grouped and treated with 25 and 5 mg/kg of YL143 in vehicle via oral gavage and i.v., respectively. Eyeground vein blood samples (0.20 mL) were collected from each animal at designed time point postdose (5, 30 min, 1, 2, 4, 8, 12, 24, 36, 48, 60, and 72 h.). Blood samples were centrifuged within 10 min at 900 g, and then, plasma was separated and stored at 4°C until analysis. Drug concentration was quantitatively detected using an API 300 mass spectrometer (Applied Biosystems, Canada) with TurboIonSpray source interface. Data acquisition and quantitation were performed using Analyst 1.4 (Applied Biosystems, Canada). All pharmacokinetic parameters were calculated by DAS 2.0 using a noncompartment model (Clinical drug research center of Shanghai University of Traditional Chinese Medicine, Shanghai, China).
Transferase-mediated deoxyuridine triphosphate-biotin nick end labeling (TUNEL) staining
Resected mouse tumors were fixed in 4% paraformaldehyde solution (Jingxin Biotech, China), then paraffin embedded, and sectioned for TUNEL staining analysis according to the instructions of the manufacturer (11684817910, Roche, Germany).
Statistical analysis
All data are displayed as the mean ± SD of at least three experiments. Differences between groups were involved one-way ANOVA with post hoc intergroup comparison using Tukey test using SPSS 17.0 (SPSS, Inc., Chicago, IL, USA). Differences with P < 0.05 were considered significant and marked as*.
Results
YL143 is a novel mutant selective, irreversible inhibitor for EGFR
YL143 (Fig. 1A) possesses a novel chemical structure optimized from XTF262 (Fig. S1), which retains its activity and selectivity on EGFRT790M and improves the oral bioavailability (Table 3, S2).
The kinase inhibitory activities of YL143 against EGFRWT, EGFRL858R, EGFR Del 19, EGFRL858R/T790M, and EGFR Del 19, T790M were evaluated using a well-established FRET-based Z’-Lyte assay. Three reported EGFR inhibitors, that is gefitinib, CO1686, and osimertinib, were used as the positive controls. Under the experimental conditions, all of the drugs exhibited similar activities and selectivity profiles to the reported data 12, 13 (Table 1, Table S1). YL143 potently inhibited EGFRL858R/T790M with an IC50 value of 2.0 ± 0.3 nmol/L, which is more potent than the reported third-generation EGFR inhibitors (i.e., CO1686 and osimertinib) by a factor of 5–7 in a parallel comparison (Fig. 1C, Table 1). Furthermore, YL143 displayed a 92.6-fold selectivity between the L858R/T790M mutant and the wild-type EGFR, while the selectivity of CO1686 and osimertinib was 10.7- and 18.3-fold, respectively.
| nmol/L (AV ± SD) | Gefitinib | CO1686 | AZD9291 | YL143 |
|---|---|---|---|---|
| EGFRWT | 10.7 ± 0.4 | 157.0 ± 22.4 | 173.7 ± 29.3 | 185.3 ± 43.4 |
| EGFRL858R | 1.3 ± 0.1 | 23.7 ± 2.1 | 6.4 ± 1.6 | 49.1 ± 4.2 |
| EGFRDel 19 | 3.8 ± 1.5 | 90.7 ± 30.0 | 3.4 ± 1.7 | 81.5 ± 10.3 |
| EGFRT790M | 134.6 ± 17.3 | 17.2 ± 1.4 | 7.9 ± 2.3 | 7.8 ± 1.1 |
| EGFRL858,T790M | 118.2 ± 7.1 | 14.6 ± 5.5 | 9.5 ± 1.8 | 2.0 ± 0.3 |
| IGF1R | >1000 | 47.5 ± 8.4 | 276.8 | >1000 |
| IR | 3.5 ± 0.5 | 12.8 ± 0.8 | 235 | 7.5 ± 0.1 |
- EGFR activity assays were performed using the FRET-based Z′-Lyte assay according to the manufacturer's instructions. The compounds were incubated with the kinase reaction mixture for 1.5 h before measurement. The data are means from two independent experiments, and the variations are below 20%.
XTF262 has been proved to be an irreversible EGFR inhibitor through inhibitor washout assay and in vitro mobility shift assay 21. To prove the irreversible binding mode of YL143 with EGFRL858R/T790M, a compound washout assay was performed on H1975 cells in vitro. The Western blotting (WB) results displayed that the activation of EGFRL858R/T790M and ERK was constantly inhibited and no EGFRL858R/T790M phosphorylation recovery was observed for 24 h after YL143 was withdrawn, strongly implying that the YL143 irreversibly bound to the EGFRL858R/T790M (Fig. 2B).
Molecular docking simulation
The computational docking studies suggested that YL143 bound to the ATP binding site of EGFR with a “U-shaped” conformation (Fig. 1B). The pyrido[2,3-d]pyrimidine-7-one core formed bidentate hydrogen bonding interactions with the “hinge” residue Met793, and the acrylamide covalently bound to the Cys797. The 5-methyl at the pyrido[2,3-d]pyrimidine-7-one was slipped into the “gatekeeper” residue Met790 which likely contributed to the selectivity of EGFRT790M over the wild-type EGFR. In addition, the right-arm 3-menthyl phenyl ring YL143 was pointed to hydrophobic core formed by residues Leu718 and Gly719. The aniline ring made hydrophobic interaction with Gly796 and Pro794, and the methoxy group extended to pocket formed by Leu 792 and Pro 794 in the hinge region.
YL143 selectively inhibited proliferation of EGFR-mutant cell lines
The proliferation inhibitory activity of YL143 was investigated in H1975 (EGFRL858R/T790M), HCC827 (EGFRdel 19), A549 (EGFRWT), and A431 (EGFRWT) cells. It was shown that YL143 strongly suppressed the proliferation of H1975 and HCC827 cells with IC50 values of 45.2 ± 27.3 and 21.1 ± 9.9 nmol/L, respectively (Table 2). However, its activity against A431 and A549 cancer cells was minor with IC50 value of over 1.0 μmol/L. These cellular data are highly consistent with the compounds’ potent and selective suppression against EGFR T790M kinase.
| nmol/L (AV ± SD) | H1975 | HCC827 | A431 | A549 |
|---|---|---|---|---|
| Gefitinib | >1000 | 6.2 ± 4.1 | >1000 | >1000 |
| AZD9291 | 40.3 ± 16.6 | 3.9 ± 3.5 | >1000 | >1000 |
| CO1686 | 41.8 ± 25.1 | 67.2 ± 19.5 | >1000 | >1000 |
| YL143 | 45.2 ± 27.3 | 21.1 ± 9.9 | >1000 | >1000 |
- The antiproliferative activities of the compounds were evaluated using CCK-8 assay. The cells were treated with compound or 0.1% DMSO for 72 h. The data were means from at least three independent experiments.
YL143 inhibited EGFR signaling pathways in H1975 cell lines
The selective EGFR L858R/T790M inhibition of YL143 was investigated in H1975, HCC827, A549, and A431 cancer cells harboring different statuses of EGFR by Western blotting analysis (Fig. 2A). It was displayed that YL143 dose-dependently inhibited the phosphorylation of EGFR and the downstream proteins Erk without obviously affecting their total proteins’ expression level in H1975 cells; however, its effect on EGFR signal pathway in A431 cells was obviously less potent.
YL143 induced G0/G1 phase arrest and apoptosis in H1975 cell lines
The effect of YL143 to induce cell cycle arrest and apoptosis in H1975 cells was investigated by flow cytometry analysis. It was shown that YL143 dose-dependently induced G0/G1 phase arrest (Fig. 3A) and apoptosis (Fig. 3B) in H1975 cells. Treatment with 300 nmol/L of YL143 for 48 h led to 82.11% G0/G1 phase arrest and 34.1% apoptosis. Western blotting analysis also showed that YL143 dose-dependently decreased the protein levels of CDK2, CDK4, cyclin D2, and cyclin E and the activating cleavage of caspase-3 and caspase-9 in H1975 cells. (Fig. 3C).
Pharmacokinetics study
Further investigation revealed that YL143 significantly improved pharmacokinetic properties compared with the previous lead molecule XTF262. The PK properties of YL143 were evaluated in rats after single administration (5 mg/kg for intravenous injection, 25 mg/kg for oral). It was shown that YL143 exhibited an optimal plasma exposure (Cmax, 160.32 μg/L, 297 nmol/L) and a half-life of 6.1 h after single oral dosing 25 mg/kg (Table 3). YL143 also displayed a good oral bioavailability of 25.0%. The Cmax(297 nmol/L) was about 4.3-fold higher than IC50 (45.2 ± 27.3 nmol/L) in H1975 cells.
| Parameter | Route (mg/Kg) | |
|---|---|---|
| P.O.(25) | I.V.(5) | |
| AUC0-∞ (μg/L*h) | 2343.03 | 1877.85 |
| T1/2 (h) | 6.13 | 1.36 |
| Tmax (h) | 6.67 | 0.08 |
| Cmax (μg/L) | 160.32 | 3267.84 |
| BA (%) | 24.95 | / |
- T1/2, half-life; Cmax, maximum concentration; Tmax, time of maximum concentration; AUC 0-∞, area under the plasma concentration–time curve; F, oral bioavailability.
YL143 suppressed the H1975 xenograft tumor growth in vivo
We further evaluated the in vivo antitumor efficacy of YL143 on H1975 cancer cells using CB17-SCID mouse xenograft models. The mice were administrated with vehicle, CO1686, or YL143 once daily via oral gavage (30 mg/kg/day, respectively) for 18 consecutive days. YL143 was well tolerated in all of the tested groups with no mortality or significant loss of body weight observed during experiment (Fig. 4B). It was shown that YL143 exhibited similar antitumor efficacy to CO1686 in the H1975 xenografted mice (Fig. 4A). TUNEL stain of the tumor tissue showed that YL143 induced apoptosis in H1975 xenograft model (Fig. 4D).
Discussion
Epidermal growth factor receptor is a well-validated target for lung cancer therapy. The reversible first-generation ATP-competitive EGFR inhibitors, that is, gefitinib and erlotinib, have achieved excellent clinical benefit in patients with NSCLC harboring EGFR mutations. The drugs significantly improve the median progression-free survival (PFS) from 4.6 to 13.1 months in patients with NSCLC with EGFR exon 21 L858 mutation (EGFRL858R) or exon 19 deletion (EGFRdel19) 24. However, approximately 60% patients suffered from drug resistance after a treatment period due to a secondary acquired EGFRT790M mutation in exon 20 25, 9. The second-generation EGFR inhibitors, such as afatinib 26, bind irreversibly with EGFR via a cysteine residue (C797) in the kinase domain. But afatinib demonstrated limited clinical efficacy in the context of acquired EGFR T790M mutation because of its relatively low maximum tolerated dose (MTD) caused by the nonselective strong suppression against wild-type EGFR. Aim to resolve the ineffectiveness of second-generation inhibitors, the third-generation drugs that selectively inhibited EGFRT790M mutants were developed. Several third-generation EGFR inhibitors such as WZ4002 11, CO1686 12, and HM61713 15 have been developed into different stages of clinical investigation, and AZD9291 has been approved by US FDA for EGFRT790M resistance patients. It has become a reliable strategy to overcome mutant resistance of NSCLCs by developing wild-type sparing EGFRT790M inhibitors.
We have previously reported XTF262 21 which displayed potent and specific EGFRL858R/T790M inhibition with approximately 100-fold selectivity over the wild-type EGFR. However, this molecule possesses unacceptable PK properties and displayed poor antiproliferation efficacy in H1975 xenograft model. Chemical structure analysis suggested that the highly planar configuration contributes greatly to its low aqueous solubility. Aim to improve the PK profiles, further structural optimization was conducted based on a high-resolution X-ray structure of XTF262-EGFRT790M complex. The efforts led to the discovery of a new derivative YL143, as a highly potent and selective EGFRT790M inhibitor with improved PK profiles. YL143 possessed a reasonable oral bioavailability value of 25.0% in rats and also retained a strong EGFRL858R/T790M inhibitory activity with an IC50 value of 2.0 ± 0.3 nmol/L and superior target selectivity (approximately 92.6-fold over the wild-type kinase). In addition, the compound also exhibited promising antiproliferative activity against H1975 cells an IC50 value of 45.2 ± 27.3 nmol/L and demonstrated promising antitumor efficacy in a H1975 xenograft model without significantly toxic signs during treatment.
In the clinical study, hyperglycemia was found in 47% and six of 238 patients for CO1686 and osimertinib, respectively 4. The hyperglycemia required dose reduction in CO1686 or addition the oral hypoglycemic agent. Further analysis suggested the hyperglycemia is due to a CO1686 metabolite (M502) possessing insulin-like growth factor receptor-1 inhibitory activity 4. YL143 displayed comparable in vivo antitumor effect to that of CO1686 but weaker hyperglycemia side effect (Fig. 4C), suggesting that YL143 might possess a better therapeutic window. It has reported that IGF1 played its functions in glucose metabolism through binding IR and IGF1R heterodimeric receptors or its own receptor IGF1R 27, 28. YL143 displayed no IGF1R kinase inhibitory activity (IC50 value >1.0 μmol/L) but exhibited an IC50 value of 7.5 ± 0.1 nmol/L against IR under our experimental condition (Table 1). Further structure modification of YL143 to decrease IR kinase activity is necessary for avoiding potential hyperglycemia adverse effects.
In conclusion, we have developed a novel EGFR inhibitor YL143, which displayed highly potent and specific EGFRT790M inhibition, and improved the oral bioavailability. YL143 also exhibited antiproliferative effect in H1975 cells and animal xenografts. YL143 may serve as a new potential lead compound for drug development overcoming EGFRL858R/T790M resistance for NSCLC patients’ treatment.
Conflict of Interest
None declared.
